SCHEDULE: SilverArc Capital Dumps Kalvista Pharma Stake

SilverArc Capital Management, LLC and Devesh Gandhi have reported a 0% ownership stake in Kalvista Pharmaceuticals, Inc., indicating a full divestment of their Class A Common Stock.

Summary

• SilverArc Capital Management, LLC and Devesh Gandhi (collectively, the 'Reporting Persons') have filed a Schedule 13G amendment indicating they no longer beneficially own any shares of Kalvista Pharmaceuticals, Inc. Class A Common Stock.
• The filing states that as of June 30, 2026, the Reporting Persons hold 0 shares, representing 0% of the class of securities.
• This indicates a complete divestment of their holdings in Kalvista Pharmaceuticals, Inc.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment filing due to the complete divestment of shares, indicating a lack of confidence or strategic shift away from the company.

Negatives

• The Reporting Persons, SilverArc Capital Management, LLC and Devesh Gandhi, have completely divested their ownership in Kalvista Pharmaceuticals, Inc., holding 0 shares as of June 30, 2026.
• This complete divestment suggests a lack of confidence or a strategic decision to exit the investment.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it solely pertains to ownership changes.

Industry Context

StockSavvy.ai notes that significant divestments by institutional investors, as indicated in this Schedule 13G filing, can sometimes signal a lack of confidence in a company's future prospects or a strategic reallocation of capital by the investor.

Stakeholder Impact

• Shareholders may view this divestment negatively, potentially leading to downward pressure on the stock price due to the perceived lack of support from a former significant holder.

Key Dates

Recommendation

The filing indicates a complete divestment by SilverArc Capital Management and Devesh Gandhi, which is a negative signal. However, without further context on the reasons for the divestment or the company's underlying performance, a 'hold' recommendation is prudent, suggesting investors monitor the situation for further developments rather than making immediate decisions based solely on this ownership change.

Keywords

Kalvista Pharmaceuticals, SilverArc Capital Management, Devesh Gandhi, Schedule 13G, Ownership, Divestment, Securities